Suggested remit: To appraise the clinical and cost effectiveness of melphalan flufenamide with dexamethasone within its marketing authorisation for treating relapsed or refractory multiple myeloma
Status In progress
Process STA 2018
ID number 3862

Provisional Schedule

Expected publication 22 June 2022

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
12 February 2021 - 12 March 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
10 March 2021 The Department for Health and Social Care has asked NICE to conduct an appraisal of Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma. Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early-August 2021 when we will write to you about how you can get involved.
05 December 2017 In progress. DHSC referral received

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance